Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.49
−$0.23 · -6.18%
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Previous close
$3.49
−$0.23 · -6.18%
After-hours
$3.53
+$0.04 · +1.15%
Oct 8, 7:38 PM ET
Regular session · ET · Market data may be delayed.
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Day range
Current $3.49
52-week range
Current $3.49
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
69
Undervalued
Sentiment
59
Mixed
Risk
66
High Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Day range
Current $3.49
52-week range
Current $3.49
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.23M USD | 135K USD | — | — | — |
| Cost of goods sold | 53K USD | — | — | — | — |
| Gross profit | 1.18M USD | 135K USD | — | — | — |
| Research and development | 7.52M USD | 9.11M USD | 5.97M USD | 2.5M USD | 2.77M USD |
| Selling, general, and administrative | 5.84M USD | 8.87M USD | 8.04M USD | 6.92M USD | 1.68M USD |
| Operating expenses | 13.36M USD | 17.98M USD | 14.21M USD | 11.61M USD | 4.45M USD |
| Interest income | 325K USD | 101K USD | — | 630 USD | — |
| Interest expense | 329K USD | 244K USD | 1.08M USD | 630K USD | 212K USD |
| Depreciation and amortization | 18K USD | — | 14.01M USD | — | — |
| Operating income | −12.18M USD | −17.84M USD | −14.21M USD | −11.61M USD | −4.45M USD |
| Net income | −12.15M USD | −24.83M USD | −26.23M USD | −12.19M USD | −4.6M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
